Literature DB >> 15956364

Comparison of the COBAS AMPLICOR MTB and BDProbeTec ET assays for detection of Mycobacterium tuberculosis in respiratory specimens.

W H F Goessens1, P de Man, J G M Koeleman, A Luijendijk, R te Witt, H P Endtz, A van Belkum.   

Abstract

The performances of the BDProbeTec ET (Becton Dickinson) and COBAS AMPLICOR MTB (Roche) were retrospectively evaluated for detecting Mycobacterium tuberculosis complex in various respiratory specimens. The BACTEC and MGIT liquid culture system (Becton Dickinson) was used as a reference method. A total of 824 respiratory specimens, comprised of sputa, bronchoalveolar lavage fluid, and bronchial and tracheal aspirates from 580 patients, were evaluated. Out of 824 clinical specimens, 109 specimens from 43 patients were culture positive for M. tuberculosis. Of these 109 specimens, 67 were smear positive, 85 were positive by the COBAS AMPLICOR MTB test, and 94 were positive by the BDProbeTec ET. Of the 715 culture-negative specimens, 17 were positive by the auramine staining, 11 were positive by the COBAS AMPLICOR MTB test, and 12 were positive by the BDProbeTec ET. After discrepancy analysis and review of the patients' clinical data, 130 specimens from 50 patients were considered "true-positive" specimens. This resulted in the following sensitivities: microscopy, 61.5%; COBAS AMPLICOR MTB test, 78.0%; and BDProbeTec ET, 86.2%. The specificities of each system, based on the clinical diagnosis, were 99.7% for microscopy, 99.9% for the COBAS AMPLICOR MTB test, and 99.9% for the BDProbeTec ET. The data presented represent a considerable number of specimens evaluated with a considerable number of culture- and auramine-positive and culture-positive and auramine-negative results and therefore give a realistic view of how the data should be interpreted in a daily routine situation. Specifically, the data with regard to the culture-positive and auramine-negative specimens are useful, because in a routine situation, auramine-negative specimens are sometimes accepted, on clinical indications, to be analyzed by an amplification method.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15956364      PMCID: PMC1151882          DOI: 10.1128/JCM.43.6.2563-2566.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  27 in total

1.  Clinical evaluation of the automated COBAS AMPLICOR MTB assay for testing respiratory and nonrespiratory specimens.

Authors:  U Reischl; N Lehn; H Wolf; L Naumann
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

2.  Strand displacement amplification and the polymerase chain reaction for monitoring response to treatment in patients with pulmonary tuberculosis.

Authors:  T J Hellyer; T W Fletcher; J H Bates; W W Stead; G L Templeton; M D Cave; K D Eisenach
Journal:  J Infect Dis       Date:  1996-04       Impact factor: 5.226

3.  Multiplex strand displacement amplification (SDA) and detection of DNA sequences from Mycobacterium tuberculosis and other mycobacteria.

Authors:  G T Walker; J G Nadeau; P A Spears; J L Schram; C M Nycz; D D Shank
Journal:  Nucleic Acids Res       Date:  1994-07-11       Impact factor: 16.971

4.  Evaluation of Roche Amplicor PCR assay for Mycobacterium tuberculosis.

Authors:  W L Wobeser; M Krajden; J Conly; H Simpson; B Yim; M D'costa; M Fuksa; C Hian-Cheong; M Patterson; A Phillips; R Bannatyne; A Haddad; J L Brunton; S Krajden
Journal:  J Clin Microbiol       Date:  1996-01       Impact factor: 5.948

5.  Rapid diagnostic tests for tuberculosis: what is the appropriate use? American Thoracic Society Workshop.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1997-05       Impact factor: 21.405

6.  Clinical evaluation of the Roche AMPLICOR PCR Mycobacterium tuberculosis test for detection of M. tuberculosis in respiratory specimens.

Authors:  J S Bergmann; G L Woods
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

7.  Diagnostic value of the strand displacement amplification method compared to those of Roche Amplicor PCR and culture for detecting mycobacteria in sputum samples.

Authors:  S Ichiyama; Y Ito; F Sugiura; Y Iinuma; S Yamori; M Shimojima; Y Hasegawa; K Shimokata; N Nakashima
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

8.  Diagnostic performance of amplified Mycobacterium tuberculosis direct test with cerebrospinal fluid, other nonrespiratory, and respiratory specimens.

Authors:  G E Pfyffer; P Kissling; E M Jahn; H M Welscher; M Salfinger; R Weber
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

9.  Detection of Mycobacterium tuberculosis in respiratory specimens by strand displacement amplification of DNA.

Authors:  J A Down; M A O'Connell; M S Dey; A H Walters; D R Howard; M C Little; W E Keating; P Zwadyk; P D Haaland; D A McLaurin; G Cole
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

10.  Chemiluminescent detection of strand displacement amplified DNA from species comprising the Mycobacterium tuberculosis complex.

Authors:  C A Spargo; P D Haaland; S R Jurgensen; D D Shank; G T Walker
Journal:  Mol Cell Probes       Date:  1993-10       Impact factor: 2.365

View more
  19 in total

1.  Is real-time PCR better than conventional PCR for Mycobacterium tuberculosis complex detection in clinical samples?

Authors:  Enrico Tortoli; Pasquale Urbano; Fiorella Marcelli; Tullia M Simonetti; Daniela M Cirillo
Journal:  J Clin Microbiol       Date:  2012-06-12       Impact factor: 5.948

2.  Evaluation of Cobas TaqMan MTB PCR for detection of Mycobacterium tuberculosis.

Authors:  Jeong Hyun Kim; Young Jae Kim; Chang-Seok Ki; Ji-Youn Kim; Nam Yong Lee
Journal:  J Clin Microbiol       Date:  2010-11-03       Impact factor: 5.948

3.  Incubation time of mycobacterial cultures: how long is long enough to issue a final negative report to the clinician?

Authors:  Gaby E Pfyffer; Franziska Wittwer
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

4.  Evaluation of the GenoType Mycobacteria Direct assay for detection of Mycobacterium tuberculosis complex and four atypical mycobacterial species in clinical samples.

Authors:  F Franco-Alvarez de Luna; P Ruiz; J Gutiérrez; M Casal
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

5.  Rapid detection of the Mycobacterium tuberculosis complex by use of quenching probe PCR (geneCube).

Authors:  Yukio Hida; Kyoko Hisada; Akihiro Shimada; Masanori Yamashita; Hideki Kimura; Haruyoshi Yoshida; Hiromichi Iwasaki; Masayuki Iwano
Journal:  J Clin Microbiol       Date:  2012-08-29       Impact factor: 5.948

6.  Clinical evaluation of TRCRapid M.TB for detection of Mycobacterium tuberculosis complex in respiratory and nonrespiratory specimens.

Authors:  Haruka Tanaka; Haruka Hirose; Yuko Kato; Saori Kida; Eiji Miyajima
Journal:  J Clin Microbiol       Date:  2010-03-03       Impact factor: 5.948

7.  Evaluation of the hyplex TBC PCR test for detection of Mycobacterium tuberculosis complex in clinical samples.

Authors:  Sabine Hofmann-Thiel; Laziz Turaev; Harald Hoffmann
Journal:  BMC Microbiol       Date:  2010-03-31       Impact factor: 3.605

8.  Comparison of 14 molecular assays for detection of Mycobacterium tuberculosis complex in bronchoalveolar lavage fluid.

Authors:  Onno W Akkerman; Tjip S van der Werf; Maria de Boer; Jessica L de Beer; Zeaur Rahim; John W A Rossen; Dick van Soolingen; Huib A M Kerstjens; Adri G M van der Zanden
Journal:  J Clin Microbiol       Date:  2013-08-21       Impact factor: 5.948

9.  Cost-effectiveness analysis of PCR for the rapid diagnosis of pulmonary tuberculosis.

Authors:  Luciene C Scherer; Rosa D Sperhacke; Antonio Ruffino-Netto; Maria Lr Rossetti; Claudia Vater; Paul Klatser; Afrânio L Kritski
Journal:  BMC Infect Dis       Date:  2009-12-31       Impact factor: 3.090

10.  Comparison of Xpert MTB/RIF with ProbeTec ET DTB and COBAS TaqMan MTB for direct detection of M. tuberculosis complex in respiratory specimens.

Authors:  Uladzimir Antonenka; Sabine Hofmann-Thiel; Laziz Turaev; Ainura Esenalieva; Mokhonim Abdulloeva; Evgeni Sahalchyk; Tarig Alnour; Harald Hoffmann
Journal:  BMC Infect Dis       Date:  2013-06-20       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.